Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin

Brooks Platt, BS; Emily Belarski, PharmD; John Manaloor, MD; Susan Ofner; Aaron E. Carroll, MD, MS; Chandy C. John, MD; James B. Wood, MD, MSCI

Abstract

IMPORTANCE Timely initiation of intravenous immunoglobulin plus aspirin is necessary for decreasing the risk of recrudescent fever and coronary artery abnormalities in children with Kawasaki disease (KD). The optimal dose of aspirin, however, remains unclear.

OBJECTIVE To evaluate whether initial treatment with low-dose compared with high-dose aspirin in children with KD is associated with an increase in fever recrudescence.

DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study of 260 children with KD at Riley Hospital for Children, Indianapolis, Indiana, between January 1, 2007, and December 31, 2018, was conducted. Children aged 0 to 18 years with a first episode of KD, identified by International Classification of Diseases, Ninth Revision and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnosis codes treated within 10 days of symptom onset with high-dose intravenous immunoglobulin plus aspirin were eligible. Patients who received an alternative diagnosis, experienced a second episode of KD, did not receive intravenous immunoglobulin plus aspirin for initial treatment, were not treated within 10 days of symptoms, or had incomplete records were excluded.

EXPOSURES High-dose (≥10 mg/kg/d) or low-dose (<10 mg/kg/d) aspirin therapy.

MAIN OUTCOMES AND MEASURES The primary outcome was recrudescent fever necessitating retreatment of KD. The secondary outcomes were coronary artery abnormalities and hospital length of stay.

RESULTS Among the 260 patients included, the median (interquartile range) age was 2.5 (1.6-4.3) years, 103 (39.6%) were girls, 166 (63.8%) were non-Hispanic white, 57 (21.9%) were African American, 22 (8.5%) were Asian, 11 (4.2%) were Hispanic, and 4 (1.5%) were of unknown race/ethnicity. One hundred-forty-two patients (54.6%) were treated with low-dose aspirin. There was no association between recrudescent fever and aspirin dose; with 39 children (27.5%) having recrudescent fever in the low-dose group compared with 26 children (22.0%) in the high-dose group (odds ratio [OR], 1.34; 95% CI, 0.76-2.37; P = .31), with similar results after adjusting for potential confounding variables (OR, 1.63; 95% CI, 0.89-2.97; P = .11). In a subset analysis of 167 children with complete KD, however, there was nearly a 2-fold difference in the odds of recrudescent fever with low-dose aspirin (OR, 1.87; 95% CI, 0.82-4.23; P = .14), although this difference did not reach statistical significance. In addition, no association was identified between treatment group and coronary artery abnormalities (low-dose, 7.4% vs high-dose, 9.4%; OR, 0.86; 95% CI, 0.48-1.55; P = .62) or median (interquartile range) length of stay (3 [3-5] days for both groups; P = .27).

CONCLUSIONS AND RELEVANCE In this study, low-dose aspirin for the initial treatment of children with KD was not associated with fever recrudescence or coronary artery abnormalities. Given the

(continued)
Abstract (continued)

potential benefits, further study of low-dose aspirin to detect potentially clinically relevant outcome differences is warranted to inform treatment decisions and guideline development.

JAMA Network Open. 2020;3(1):e1918565. doi:10.1001/jamanetworkopen.2019.18565

Introduction

Kawasaki disease (KD) is an acute systemic vasculitis of unknown cause with the potential for serious sequelae, including coronary artery abnormalities, in 15% to 25% of untreated patients.1,2 With timely initiation of treatment, however, the risk of coronary artery abnormalities is greatly reduced. In the United States, the standard of care for initial treatment of KD is high-dose intravenous immunoglobulin, along with acetylsalicylic acid (aspirin).1 Although the role and dose of intravenous immunoglobulin, 2 g/kg, are well established and have been shown to significantly reduce the risk of coronary artery abnormalities,3-8 the optimal dose of aspirin is unclear, resulting in significant practice variation.1,5,9,10

In higher doses, aspirin is used as an anti-inflammatory agent, while at lower doses it has antithrombotic effects. Both of these actions are thought to be useful in the initial stages of KD. Given concerns for adverse drug effects with aspirin,11 especially at higher doses, questions regarding the utility and optimal dose of aspirin have arisen. Although multiple studies have shown no difference in coronary artery abnormality risk between low- and high-dose aspirin,9,12,13 the effect on recrudescent fever, especially in the US population, is understudied.3,4,14 We therefore sought to evaluate whether the dose of aspirin was associated with recrudescent fever, hypothesizing that, given its the anti-inflammatory properties, high-dose aspirin would be associated with a decrease in recrudescent fever compared with low-dose aspirin in children with KD.

Methods

Study Design and Population

This was a single-center, retrospective cohort study of children aged 0 to 18 years with KD who were treated at Riley Hospital for Children, Indianapolis, Indiana, between January 1, 2007, and December 31, 2018. Potential study participants were identified by International Classification of Diseases, Ninth Revision (ICD-9) and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) (446.1 and M30.3, respectively) diagnosis codes and were included in the study if they were diagnosed with a first episode of KD and treated within 10 days of symptom onset with high-dose (2 g/kg) intravenous immunoglobulin plus aspirin. Patients were excluded if they had an alternative diagnosis, experienced a second episode of KD (recurrent KD), did not receive high-dose intravenous immunoglobulin plus aspirin or received adjunctive medicine (eg, corticosteroids) for the initial treatment of KD, were not treated within 10 days of symptom onset, or had incomplete records. All records were reviewed for eligibility by the study team. The study was approved by the Indiana University Institutional Review Board, with a waiver of informed patient consent as a retrospective review and because of the feasibility of obtaining informed consent from the participants. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Treatment Groups and End Points

Patients who met inclusion criteria were placed into 2 groups: high-dose (≥10 mg/kg/d, which encompasses both high- and medium-dosegroups) or low-dose (<10 mg/kg/d) aspirin based on the initial dose of aspirin given for the treatment of KD. Patients treated with medium-dose aspirin were grouped with high-dose because both doses are used to treat inflammation.
The primary end point was the recrudescence of fever, defined as a temperature of 38 °C or higher orally or rectally or 37.5 °C axillary necessitating retreatment for KD within 14 days of initial treatment. The secondary end points of this study were coronary artery abnormality seen at any time during follow-up as well as hospital length of stay.

Data Collection
Using the electronic medical record, patients were screened for eligibility; if inclusion criteria were met, the following data were collected: demographic characteristics (age, race/ethnicity [defined by the investigators after medical record review], and sex), symptoms before admission (fever, exanthem, conjunctivitis, mucous membrane changes, adenopathy, extremity swelling, and peeling), fever duration before treatment, dose of intravenous immunoglobulin, brand of intravenous immunoglobulin, dose of aspirin, recrudescence of fever necessitating retreatment of KD, type of retreatment, laboratory results (white blood cell count, hemoglobin level, platelet count, and erythrocyte sedimentation rate and C-reactive protein, aspartate aminotransferase, alanine aminotransferase, albumin, and bilirubin levels), echocardiogram results (initial and follow-up), and dates of hospital admission and discharge.

Statistical Analysis
Data were summarized for the high- and low-dose aspirin groups. Continuous variables were tested for a difference between groups by means of the independent t test for normally distributed data and Mann–Whitney test or Wilcoxon rank sum test for nonnormally distributed data. Categorical variables were tested by means of χ² or Fisher exact test. Bivariate logistic models were fit for the primary outcome of recrudescent fever. A multivariable regression model was built by including the indicator variable for low-dose aspirin and all variables that were significant at the .30 level in bivariate models. Except for the term low-dose aspirin, which we required to remain in the model, backward variable selection was used to remove nonsignificant variables until all remaining variables were significant at the .05 level with 2-tailed, unpaired testing.

Similar analytic methods were used for the analysis of the secondary outcome of abnormal echocardiogram. Plots examining the linearity assumption of the continuous independent variables with the logit of abnormal echocardiogram showed nonlinear patterns. To address this outcome, continuous variables were coded as categorical so that the resulting associations were linear with the logit of the dependent variable.

Length of stay was log transformed because the data were right skewed. Bivariate regression models were fit to the log of length of stay. Residual plots were examined to assess model assumptions of homogeneity of variance and normality (eFigure in the Supplement). When building a multivariable model, a similar approach for variable selection was used for length of stay. Data analysis was performed with SAS, version 9.4 (SAS Institute Inc).

Results
Population Characteristics
A total of 673 patients were identified by ICD-9 and ICD-10 codes and screened for eligibility, and 413 of those patients were excluded. Of the excluded patients, 135 received an alternative final diagnosis, 184 had absent or incomplete medical records, 49 had no record of KD, 42 received treatment after 10 days of fever or received treatment other than intravenous immunoglobulin, 2 g/kg, plus aspirin, and 3 were excluded owing to having recurrent KD.

Table 1 presents the characteristics of the study population. Among the 260 patients included, the median (interquartile range [IQR]) age was 2.5 (1.6–4.3) years, 103 (39.6%) were girls, 166 (63.8%) were non-Hispanic white, 57 (21.9%) were African American, 22 (8.5%) were Asian, 11 (4.2%) were Hispanic, and 4 (1.5%) were of unknown race/ethnicity. The median (IQR) dose of intravenous immunoglobulin was 1.99 (1.92–2.07) mg/kg. Of the 260 included patients, 142 patients
(54.6%) received low-dose aspirin (<10 mg/kg/d) and 118 patients (45.4%) received high-dose aspirin (≥10 mg/kg/d). The median (IQR) daily dose of aspirin in the low-dose group was 4.4 (3.6-5.1) mg/kg; the median (IQR) daily dose in the high-dose group was 75.5 (41.7-86.1) mg/kg. Most children in the low-dose aspirin group received 3 to 5 mg/kg/d and were treated earlier than 2016, while most in the high-dose group received greater than 50 to 100 mg/kg/d and were treated after 2015 (Table 2 and Figure). Treatment groups were similar with respect to age, sex, race/ethnicity, fever duration prior to intravenous immunoglobulin treatment, coronary artery abnormality at diagnosis, white blood cell count, hemoglobin level, platelet count, erythrocyte sedimentation rate, and alanine and aspartate aminotransferase levels. Most patients in both groups received Privigen brand intravenous immunoglobulin. In addition, clinical presentation was similar between the 2 groups with respect to the proportion of exanthem, mucous membrane changes, cervical lymphadenopathy, extremity

| Table 1. Characteristics of Study Population |
|---------------------------------------------|
| Characteristic                              | Overall (N = 260) | Low-Dose (n = 142 [54.6%]) | High-Dose (n = 118 [45.4%]) | P Value<sup>a</sup> |
| Demographic                                |                 |                             |                              |                   |
| Age, y                                      |                 |                             |                              |                   |
| Median (IQR)                                | 2.5 (1.6-4.3)   | 2.4 (1.5-4.4)               | 2.7 (1.7-4.2)                | .66               |
| <1 y, No. (%)                               | 40 (15.4)       | 24 (16.9)                   | 16 (13.6)                    | .46               |
| Sex, No. (%)                                |                 |                             |                              |                   |
| Female                                      | 103 (39.6)      | 61 (43.0)                   | 42 (35.6)                    | .23               |
| Male                                        | 157 (60.4)      | 81 (57.0)                   | 76 (64.4)                    |                   |
| Race/ethnicity, No. (%)                     |                 |                             |                              |                   |
| Non-Hispanic white                         | 166 (63.8)      | 98 (69.0)                   | 79 (66.9)                    |                   |
| African American                           | 57 (21.9)       | 30 (21.1)                   | 27 (22.9)                    |                   |
| Asian                                       | 22 (8.5)        | 12 (8.5)                    | 10 (8.5)                     |                   |
| Unknown race                                | 4 (1.5)         | 2 (1.4)                     | 2 (1.7)                      |                   |
| Hispanic                                    | 11 (4.2)        | 9 (6.3)                     | 2 (1.7)                      | .56               |
| Unknown ethnicity                           | 4 (2.7)         | 2 (1.8)                     | 2 (5.1)                      |                   |
| Clinical                                    |                 |                             |                              |                   |
| Days of fever, median (IQR)<sup>b</sup>    | 6.0 (5.0-8.0)   | 6.0 (5.0-8.0)               | 6.0 (5.0-8.0)                | .94               |
| Intravenous immunoglobulin brand, No. (%)   |                 |                             |                              |                   |
| Privigen                                    | 159 (61.1)      | 91 (64.1)                   | 68 (57.6)                    |                   |
| Gammagard                                   | 34 (13.1)       | 19 (13.4)                   | 15 (12.7)                    |                   |
| Octagam                                     | 8 (3.1)         | 8 (5.6)                     | 0                            |                   |
| Carimune                                    | 3 (1.2)         | 3 (2.1)                     | 0                            |                   |
| Other or unknown                            | 59 (22.7)       | 21 (14.8)                   | 38 (32.2)                    |                   |
| Aspirin dose, median (IQR), mg/kg/d         | 6.5 (4.4-56.5)  | 4.4 (3.6-5.1)               | 75.5 (41.7-86.1)             | <.001             |
| Incomplete KD                               | 93 (35.8)       | 41 (28.9)                   | 52 (44.1)                    | .01               |
| Coronary artery abnormality at diagnosis    | 58 (22.3)       | 30 (21.1)                   | 28 (23.7)                    | .62               |
| Laboratory values, median (IQR)             |                 |                             |                              |                   |
| WBC, /μL                                    | 14.5 (10.8-18.2)| 13.8 (1.6-18.4)             | 15.0 (11.0-17.8)             | .34               |
| Hemoglobin, g/dL                            | 11.0 (10.3-11.6)| 11.0 (1.3-11.5)             | 11.0 (10.3-11.7)             | .56               |
| Platelets, ×10<sup>3</sup>/μL               | 355.0 (292.0-450.0)| 352.0 (282.0-439.0)       | 357.0 (297.0-468.0)          | .36               |
| ESR, mm/h                                   | 65.0 (47.0-87.0)| 63.0 (52.0-82.0)            | 65.0 (42.0-93.0)             | .72               |
| CRP, mg/L                                   | 12.5 (6.2-20.1) | 1.0 (4.8-18.4)              | 14.7 (7.4-21.4)              | .005              |
| Albumin, g/dL                               | 3.3 (2.9-3.7)   | 3.1 (2.7-3.6)               | 3.6 (3.1-3.8)                | <.001             |
| AST, U/L                                    | 36.0 (25.0-60.5)| 35.0 (26.0-59.0)            | 38.0 (23.0-61.5)             | .98               |
| ALT, U/L                                    | 44.0 (17.0-99.0)| 45.0 (19.0-88.0)            | 42.0 (17.0-110.0)            | .47               |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; KD, Kawasaki disease; WBC, white blood cell count.

SI conversion factors: To convert albumin to grams per liter, multiply by 10; ALT to microkatal per liter, multiply by 0.0167; AST to microkatal per liter, multiply by 0.0167; CRP to nanomoles per liter, multiply by 9.524; hemoglobin to grams per liter, multiply by 10; platelets to ×10<sup>9</sup> per liter, multiply by 1; and WBC to ×10<sup>9</sup> per liter, multiply by 0.001.

<sup>a</sup> P value determined using independent t test for normally distributed data and Mann-Whitney test for nonnormally distributed data.

<sup>b</sup> Days of fever before treatment with intravenous immunoglobulin.
changes, nonpurulent conjunctivitis, extremity peeling, and groin peeling (Table 3). The high-dose group, however, exhibited a higher proportion of patients with incomplete KD compared with the low-dose group at 44.1% (n = 52) and 28.9% (n = 41), respectively (P = .01), and had a higher median albumin level (3.6 vs 3.1 g/dL [to convert to grams per liter, multiply by 10], P < .001). There were no adverse effects due to aspirin in either treatment group.

Recurrent Fever
Recurrent fever, the primary outcome, was observed in 65 patients (25.0%) in the overall study population (Table 4). Treatment with low-dose aspirin was not associated with an increase in fever recurrence vs high-dose aspirin (39 [27.5%] vs 26 [22.0%]; odds ratio [OR], 1.34; 95% CI, 0.76-2.37; P = .31). After adjusting for age less than 1 year and incomplete KD, variables that remained

| Aspirin Group | Patients, No. (%) |
|---------------|-------------------|
| Low dose, mg/kg/d | |
| No. 142 | |
| <3 13 (9.2) | |
| 3-5 89 (62.7) | |
| >5-10 40 (28.2) | |
| High dose, mg/kg/d | |
| No. 118 | |
| >10-30 6 (5.1) | |
| >30-50 42 (35.6) | |
| >50-100 65 (55.1) | |
| >100 5 (4.2) | |

Figure. Aspirin Dosing By Year

Table 3. Clinical Symptoms by Group

| Clinical Presentation | Patients, No. (%) | Low Dose (n = 142) | High Dose (n = 118) | P Value |
|-----------------------|------------------|-------------------|-------------------|---------|
| Exanthem              | 239 (91.9)       | 133 (93.7)        | 106 (89.8)        | .26     |
| Mucous membrane changes | 214 (82.3)      | 120 (84.5)        | 94 (79.7)         | .31     |
| Swelling              | 164 (63.1)       | 96 (67.6)         | 68 (57.6)         | .10     |
| Cervical lymphadenopathy | 103 (39.6)     | 54 (38.0)         | 49 (41.5)         | .57     |
| Conjunctivitis        | 223 (85.8)       | 124 (87.3)        | 99 (83.9)         | .43     |
| Extremity peeling     | 25 (9.6)         | 15 (10.6)         | 10 (8.5)          | .57     |
| Groin peeling         | 41 (15.8)        | 20 (14.1)         | 21 (17.8)         | .41     |
in the model after backward selection, the odds of recrudescent fever remained similar between the 2 treatment groups (OR, 1.63; 95% CI, 0.89-2.97; \( P = .11 \)).

We performed a stratified analysis for children with complete and incomplete KD. In 167 children with complete KD, treatment with low-dose aspirin, after adjusting for age less than 1 year, was associated with nearly a 2-fold increase in recurrent fever, but this difference did not reach statistical significance (OR, 1.87; 95% CI, 0.82-4.23; \( P = .14 \)). In 93 children with incomplete KD, we found no association of recurrent fever and dosing regimens (OR, 1.33; 95% CI, 0.53-3.36; \( P = .54 \)). In addition, to investigate for an interaction between aspirin dosing and KD type (complete vs incomplete), we added an interaction term to the model and did not find a difference in recrudescent fever between dosing groups.

**Coronary Artery Abnormality and Hospital Length of Stay**

With respect to the secondary outcomes, of the total study population, 8.3% had a coronary artery abnormality at follow up and the median (IQR) length of hospitalization was 3 (3-5) days. Aspirin dose was not associated with an increase in coronary artery abnormalities at follow-up, as the proportion of patients with coronary artery abnormalities in both groups (7.4% in the low-dose group and 9.4% in the high-dose group) was similar (OR, 0.86; 95% CI, 0.48-1.55; \( P = .62 \)). After adjusting for incomplete KD, there was no association between coronary artery abnormalities and treatment group (OR, 1.02; 95% CI, 0.55-1.87; \( P = .96 \)). Stratified by KD type, there was no association between coronary artery abnormalities and treatment group for either complete KD (OR, 1.28; 95% CI, 0.53-3.08; \( P = .58 \)) or incomplete KD (OR, 0.81; 95% CI, 0.34-1.92; \( P = .63 \)). The median (IQR) length of hospital stay for both the low-dose and high-dose groups was 3 (3-5) days (\( P = .27 \)) and remained unchanged after multivariable adjustment (adjusted for platelet count, fever duration, and incomplete KD).

**Discussion**

The major findings of this study are that treatment with low-dose aspirin (<10 mg/kg/d) along with high-dose intravenous immunoglobulin within 10 days of symptoms in children with KD was not associated with an increase in recrudescent fever compared with children treated with high-dose (\( \geq 10 \) mg/kg/d) aspirin. In addition, there was no association between aspirin dose and length of hospital stay or coronary artery abnormalities at follow-up in children with KD. When stratified by KD type, initial treatment with low-dose aspirin in children with complete KD was associated with a nearly 2-fold higher odds of recrudescent fever, although this increase was not statistically significant. To our knowledge, this study is unique in investigating aspirin dosing and fever recrudescence within a single US institution and is the largest cohort of such patients.

During the acute, inflammatory phase of KD, the goal of treatment is to decrease systemic inflammation and prevent or reduce vascular damage and thrombosis. To that end, for more than 3 decades, potent anti-inflammatory medications—high-dose intravenous immunoglobulin and aspirin—have been a mainstay of initial KD treatment.\(^{15,16}\) The role and mechanisms by which these 2

**Table 4. Outcomes of Study Population**

| Outcome                              | Overall (N = 260) | Low-Dose (n = 142) | High-Dose (n = 118) | Unadjusted OR (95% CI)\(^{a}\) | \( P \) Value | Adjusted OR (95% CI) \( P \) Value |
|--------------------------------------|------------------|--------------------|--------------------|-------------------------------|---------------|-----------------------------------|
| Recrudescent fever, No. (%)          | 65 (25.0)        | 39 (27.5)         | 26 (22.0)         | 1.34 (0.76-2.37)               | .31           | 1.63 (0.89-2.97) \( P = .11^{b} \) |
| Coronary artery abnormality, No. (%)\(^{c}\) | 20/242 (8.3)    | 10/135 (7.4)     | 10/107 (9.4)      | 0.86 (0.48-1.55)               | .62           | 1.02 (0.55-1.87) \( P = .96^{d} \) |
| Length of hospital stay, median (IQR), d | 3.0 (3.0-5.0)   | 3.0 (3.0-5.0)    | 3.0 (3.0-5.0)     | NA                            | .27           | NA \( P = .56^{e} \)               |

Abbreviations: IQR, interquartile range; NA, not applicable; OR, odds ratio.

\(^{a}\) High-dose aspirin is the reference.

\(^{b}\) Adjusted for age younger than 1 year and incomplete Kawasaki disease using regression modeling.

\(^{c}\) Any abnormality at 2- or 6-week follow-up. Eighteen patients did not have follow-up echocardiograms.

\(^{d}\) Adjusted for incomplete Kawasaki disease using regression modeling.

\(^{e}\) Adjusted for platelet count, fever duration, and incomplete Kawasaki disease.
medications work in KD remain elusive. Despite this uncertainty, there is good evidence regarding optimal dosing and efficacy of intravenous immunoglobulin in reducing coronary artery abnormalities.8,15,16 The utility and optimal dosing for aspirin, however, is less clear.3,4,9 As such, substantial variation exists in the dosing and duration of aspirin around the world.1 While there is evidence that aspirin dosing does not affect the rate of coronary artery abnormalities,9 the effect on recrudescent fever, especially in a US population, has not been well studied and has potential ramifications on the need for retreatment, length of stay, and cost. In addition, although high-dose aspirin is generally well tolerated in children, reports of adverse effects, including gastrointestinal bleeding and Reye syndrome, have been documented.17,18 Low-dose aspirin, meanwhile, has not been associated with Reye syndrome,1 is administered once daily, and may be better tolerated. Given these potential advantages, investigation into the outcomes of children treated with low-dose aspirin is important.

The findings in this study support a growing body of literature suggesting that initial treatment with low-dose aspirin may not be associated with poor outcomes in children with KD.5,9,19 One explanation is that the major anti-inflammatory effects in the initial KD treatment regimen come from intravenous immunoglobulin, which sufficiently decreases systemic inflammation regardless of aspirin dosing. Another possibility is that low-dose aspirin, although thought to mainly work on platelet function, has enough anti-inflammatory properties to decrease the odds of fever recrudescence similar to high-dose aspirin. Further investigation into the mechanisms by which intravenous immunoglobulin and aspirin work to decrease systemic inflammation in KD is needed.

Others have looked at the association between aspirin dosing and recrudescence fever in children with KD3-6,14; however, the lack of control groups, differing intravenous immunoglobulin regimens, and multiple treatment centers have limited the conclusions that can be drawn. As a large, tertiary care children's hospital in the United States serving a diverse patient population with a large number of cases of KD per year, our group is well positioned to conduct comparative research in this population. Before 2016, there was substantial variation in aspirin dosing within our center. After 2016, our group came to consensus on treating patients with KD initially with high-dose (80-100 mg/kg/d) followed by medium-dose (30-50 mg/kg/d) aspirin. Thus, a strength of our study is the large number of patients available for evaluation within a single US center, eliminating the potential bias by treatment center and potentially increasing generalizability among US centers.

Limitations
This study has limitations. After a large number of patients were excluded, our study was powered to detect an absolute risk difference of 11% or more (OR, ≥1.75). Thus, smaller differences in fever recrudescence would not be detected between treatment groups if present. Also, noting that treatment with low-dose aspirin in children with complete KD was associated with nearly a 2-fold increase in fever recrudescence, it may be that patients who truly have KD, rather than those with an unidentified, alternative diagnosis but treated for KD, have a decreased risk of fever recrudescence when treated with high-dose aspirin. Given the challenges in diagnosis, especially for incomplete KD, as well as the imbalance in KD type between treatment groups in our study, this association was not seen. A larger sample size would be required to determine whether a more subtle, but potentially clinically relevant, difference in fever recrudescence between treatment groups is present.

In addition, as with any retrospective cohort study, it can be difficult to control for differences between treatment groups. Although the only significant clinical difference between treatment groups was the number of incomplete KD cases, which was controlled for during regression analysis, other variables could have the potential to confound the results. Because most patients treated with low-dose aspirin were diagnosed prior to 2016, secular trends in treatment have the potential to introduce bias. With that said, other than aspirin dosing, KD treatment in our group remained consistent during the study period, with many of the same clinicians providing care throughout the study. Also, patient selection via ICD-9 and ICD-10 codes, although common for this type of study, has the potential to exclude patients with KD that is not coded properly. Given the large number of
patients we excluded owing to inappropriate coding, this issue is a concern, but should not skew to one treatment group over the other.

Conclusions

Initial treatment with low-dose aspirin, along with high-dose intravenous immunoglobulin, in children with KD did not appear to be associated with an increase in fever recrudescence or coronary artery abnormalities. Given the potential advantages, low-dose aspirin is an attractive option as initial therapy for KD; however, future studies powered to detect more subtle, yet possibly clinically relevant, differences in fever recrudescence are warranted.

ARTICLE INFORMATION

Accepted for Publication: November 8, 2019.

Published: January 3, 2020. doi: 10.1001/jamanetworkopen.2019.18565

Open Access: This is an open access article distributed under the terms of the CC BY License. © 2020 Platt B et al. JAMA Network Open.

Corresponding Author: James B. Wood, MD, MSCI, Pediatric and Adolescent Comparative Effectiveness Research, 410 W 10th St, HTS Building 2000A, Indianapolis, IN 46202 (woodjb@iu.edu).

Author Affiliations: Indiana University School of Medicine, Indianapolis (Platt, Manaloor, Carroll, John, Wood); Indiana University Health, Indianapolis (Belarski); Ryan White Center for Pediatric Infectious Diseases and Global Health, Indiana University School of Medicine, Indianapolis (Manaloor, John, Wood); Department of Biostatistics, Indiana University School of Medicine, Indianapolis (Ofner); Center for Pediatric and Adolescent Comparative Effectiveness Research, Indiana University School of Medicine, Indianapolis (Carroll, Wood).

Author Contributions: Mr Platt and Dr Wood had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Platt, Belarski, John, Wood.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Platt, Belarski, Ofner, Wood.
Critical revision of the manuscript for important intellectual content: Platt, Manaloor, Carroll, John, Wood.
Statistical analysis: Ofner, Wood.
Administrative, technical, or material support: Belarski, Carroll.
Supervision: Manaloor, Carroll, John, Wood.

Conflict of Interest Disclosures: None reported.

REFERENCES

1. McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999. doi:10.1161/CIR.0000000000000484

2. Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol. 2016;67(14):1738-1749. doi:10.1016/j.jacc.2015.12.073

3. Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics. 2004;114(6):e689-e693. doi:10.1542/peds.2004-1037

4. Lee G, Lee SE, Hong YM, Sohn S. Is high-dose aspirin necessary in the acute phase of Kawasaki disease? Korean Circ J. 2013;43(3):182-186. doi:10.4070/kcj.2013.43.3.182

5. Saulsbury FT. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome. Clin Pediatr (Philo). 2002;41(8):597-601. doi:10.1177/000992280204100807
6. Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH. High-dose aspirin is associated with anemia and does not confer benefit to disease outcomes in Kawasaki disease. *PLoS One.* 2015;10(12):e0144603. doi:10.1371/journal.pone.0144603

7. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. *Pediatrics.* 1995;96(6):1057-1061.

8. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. *J Pediatr.* 1997;131(6):888-893. doi:10.1016/S0022-3476(97)70038-6

9. Dallaire F, Fortier-Morissette Z, Blais S, et al. Aspirin dose and prevention of coronary abnormalities in Kawasaki disease. *Pediatrics.* 2017;139(6):e20170098. doi:10.1542/peds.2017-0098

10. Research Committee of the Japanese Society of Pediatric Cardiology; Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). *Pediatr Int.* 2014;56(2):135-158. doi:10.1111/ped.12317

11. Scuccimarri R. Kawasaki disease. *Pediatr Clin North Am.* 2012;59(2):425-445. doi:10.1016/j.pcl.2012.03.009

12. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. *Pediatrics.* 1979;63(2):175-179.

13. Ichida F, Fatica NS, Engle MA, et al. Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin. *Pediatrics.* 1987;80(6):828-835.

14. Dhanrajani A, Chan M, Pau S, Ellsworth J, Petty R, Guzman J. Aspirin dose in Kawasaki disease: the ongoing battle. *Arthritis Care Res (Hoboken).* 2018;70(10):1536-1540. doi:10.1002/acr.23504

15. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. *Lancet.* 1984;2(8411):1055-1058. doi:10.1016/S0140-6736(84)91504-6

16. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. *N Engl J Med.* 1986;315(6):341-347. doi:10.1056/NEJM198608073150601

17. Wei CM, Chen HL, Lee PI, Chen CM, Ma CY, Hwu WL. Reye's syndrome developing in an infant on treatment of Kawasaki syndrome. *J Paediatr Child Health.* 2005;41(5-6):303-304. doi:10.1111/j.1440-1754.2005.00617.x

18. Matsubara T, Mason W, Kashihi IA, Kligerman M, Burns JC. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. *J Pediatr.* 1996;128(5, pt 1):701-703. doi:10.1016/S0022-3476(96)80140-5

19. Ogata S, Tremoulet AH, Sato Y, et al. Coronary artery outcomes among children with Kawasaki disease in the United States and Japan. *Int J Cardiol.* 2013;168(4):3825-3828. doi:10.1016/j.ijcard.2013.06.027

**SUPPLEMENT.**

eFigure. Residual Plots from Log(LOS) = Dose + Platelets + Fever Duration + Complete KD